IL300881A - Methods for preventing embolization of cholesterol crystals with cyclodextrins - Google Patents

Methods for preventing embolization of cholesterol crystals with cyclodextrins

Info

Publication number
IL300881A
IL300881A IL300881A IL30088123A IL300881A IL 300881 A IL300881 A IL 300881A IL 300881 A IL300881 A IL 300881A IL 30088123 A IL30088123 A IL 30088123A IL 300881 A IL300881 A IL 300881A
Authority
IL
Israel
Prior art keywords
cyclodextrin
individual
beta
amount
hydroxypropyl
Prior art date
Application number
IL300881A
Other languages
English (en)
Hebrew (he)
Original Assignee
Beren Therapeutics P B C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beren Therapeutics P B C filed Critical Beren Therapeutics P B C
Publication of IL300881A publication Critical patent/IL300881A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Steroid Compounds (AREA)
IL300881A 2020-08-27 2021-08-27 Methods for preventing embolization of cholesterol crystals with cyclodextrins IL300881A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063071243P 2020-08-27 2020-08-27
PCT/US2021/048075 WO2022047244A1 (en) 2020-08-27 2021-08-27 Methods for the prevention of cholesterol crystal embolization with cyclodextrins

Publications (1)

Publication Number Publication Date
IL300881A true IL300881A (en) 2023-04-01

Family

ID=80352440

Family Applications (1)

Application Number Title Priority Date Filing Date
IL300881A IL300881A (en) 2020-08-27 2021-08-27 Methods for preventing embolization of cholesterol crystals with cyclodextrins

Country Status (11)

Country Link
US (1) US20230302042A1 (cg-RX-API-DMAC10.html)
EP (1) EP4203973A4 (cg-RX-API-DMAC10.html)
JP (1) JP7895334B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230096976A (cg-RX-API-DMAC10.html)
CN (1) CN116635007A (cg-RX-API-DMAC10.html)
AU (1) AU2021331485A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023003490A2 (cg-RX-API-DMAC10.html)
CA (1) CA3190764A1 (cg-RX-API-DMAC10.html)
IL (1) IL300881A (cg-RX-API-DMAC10.html)
MX (1) MX2023002420A (cg-RX-API-DMAC10.html)
WO (1) WO2022047244A1 (cg-RX-API-DMAC10.html)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877778A (en) * 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
WO2013155485A2 (en) * 2012-04-13 2013-10-17 Alessia Fornoni Method of using cyclodextrin

Also Published As

Publication number Publication date
CA3190764A1 (en) 2022-03-03
CN116635007A (zh) 2023-08-22
WO2022047244A1 (en) 2022-03-03
MX2023002420A (es) 2023-07-11
JP2023543132A (ja) 2023-10-13
US20230302042A1 (en) 2023-09-28
EP4203973A4 (en) 2024-08-21
BR112023003490A2 (pt) 2023-05-09
JP7895334B2 (ja) 2026-07-27
AU2021331485A1 (en) 2023-03-23
EP4203973A1 (en) 2023-07-05
KR20230096976A (ko) 2023-06-30

Similar Documents

Publication Publication Date Title
JP7487264B2 (ja) ５－コレステン－３，２５－ジオール，３－サルフェート（２５ｈｃ３ｓ）又は薬学的に許容される塩及び少なくとも１種の環状オリゴ糖を含む組成物
US20230330133A1 (en) Methods for the treatment of cholesterol crystal embolization with cyclodextrins
CN108366963A (zh) 包含丹曲林的水性组合物
WO2016110225A1 (zh) 一种磺酰胺类药物组合物
US20230375576A1 (en) Methods for the treatment of familial heterozygous and homozygous hypercholesterolemia with cyclodextrins
US20230302042A1 (en) Methods for the prevention of cholesterol crystal embolization with cyclodextrins
US11752122B2 (en) N-acetylcysteine attenuates aortic stenosis progression by inhibiting shear-mediated TGF-beta activation and signaling
EP4313104B1 (en) Dc009 for treating acute ischemic stroke
US20240000826A1 (en) Methods for the treatment of cardiovascular disease with cyclodextrins
TW202342072A (zh) 以環糊精治療高三酸甘油脂血症之方法